HPHCI team members will attend the 42nd Annual ISPE Conference in Milan, Italy. Below is a schedule of HPHCI-led and co-authored presentations and posters. If you would like to meet with us in Milan, please contact us at rwe@hphci.harvard.edu.
Monday, August 31, 2026
- Oral Presentation: Effectiveness and Safety of Sustained Use of SGLT2 Inhibitors in Older Adults with Type 2 Diabetes Mellitus / Hsin-Yi Huang, PhD / 11:30 AM - 11:45 AM / Brown 1+2, Level 2
- Oral Presentation: Tree-Based Safety Signal Identification for Infliximab Biosimilar vs. Reference Products / Ashley I. Michnick, PhD / 11:45 AM - 12:00 PM / Amber 1+2, Level 2
- Oral Presentation: Pregnancy Outcomes after Pfizer-BioNTech Monovalent COVID-19 Vaccination During Pregnancy in the United States / Mayura Shinde, PhD / 4:00 PM – 4:15 PM / Space 1, Level 0
- Oral Presentation: Effects of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists on Select Effectiveness and Safety Outcomes in Solid Organ Transplant Recipients with Post-Transplant Diabetes Mellitus / Ting-Ting Wu, PharmD, PhD / 11:45 AM - 12:00 PM / Space 4, Level 0
- Symposium: (SW-2E) Data Are Not Enough – Communication Practices for Pharmacoepidemiologists in a Complex Information Ecosystem / Elizabeth Bell, PhD / 5:15 PM - 6:45 PM / Space 2, Level 0
- Poster Session A: 12:00 PM - 1:30 PM in the Exhibit Hall
- (A-241) Combining treatment propensity scores and clone-censor-weighting to evaluate treatment duration in active comparator studies / Sophie Mayer, PhD
- (A-409) Use of angiotensin receptor blockers and risk of lung cancer: a target trial emulation study / Yinchu Cheng, PhD
- (A-082) Comparative Effectiveness of SGLT2i, GLP-1, DPP4i, and SU on Cardiovascular Outcomes in Adults with Severe Mental Illness, Using a Clone-Censor-Weight Approach (HPHCI collaborated) / Yueh-Yi Chiang, BSPharm
- (A-243) Evaluating Data-driven Automated Discovery of Disconnected Negative Controls Using Plasmode Simulations / Jeong-eun Park, MPH, PhD
- (A-212) Early Utilization Patterns and Effect on Cognition of Donanemab in Early AD: A Real-World Electronic Health Record Study in the US / Sonal Singh, MD
Tuesday, September 1, 2026
- Oral Presentation: Risk of Myocarditis/Pericarditis After Receipt of Pfizer-BioNTech COVID-19 Vaccine: Results from a Post-approval Safety Study in the US / J. Bradley Layton, PhD / 8:15 AM – 8:20 AM / Space 3, Level 0
- Oral Presentation: Associations of Pfizer-BioNTech COVID-19 Vaccine with Birth Outcomes: Results from a Post-approval Safety Study in the US / Alicia W. Gilsenan, PhD / 8:25 AM – 8:30 AM / Space 3, Level 0
- Oral Presentation: Tree-Based Scan Statistics to Detect Prescribing Cascades Following Initiation of Novel Glucose Lowering Drugs / Qingke Demi He, MPharm / 9:30 AM - 9:45 AM / Space 4, Level 0
- Poster Session B: 11:30 AM - 1:00 PM in the Exhibit Hall
- (B-251) Improving Confounding Control in User vs. Non-User Comparison in Pharmacoepidemiologic Studies – Single-Dispensing Users as Proxy Non-Users / Hsiu-Ting Chien
- (B-050) The Danish Infection Cohort: A Resource for Population-Based Epidemiology / Noelle Cocoros, MPH, DSc
- (B-418) The Safety of the 20-Valent Pneumococcal Conjugate Vaccine in Adults: A Data Mining Study in the US Vaccine Safety Datalink / Noelle Cocoros, DSc, MPH
- (B-422) Validation of a Claims-Based Algorithm for Myocarditis/Pericarditis and Assessment of the Impact of Outcome Misclassification in a US Postapproval Study of COVID-19 Vaccine Safety / Candace C. Fuller, PhD
- (B-421) Risk-Factor-Stratified Positive Predictive Values of an Algorithm for Guillain-Barré Syndrome / Candace Fuller, PhD
- (B-079) Prevalence of Cutaneous Lupus Erythematosus in U.S. Pediatric and Adult Populations Using the FDA’s Sentinel Distributed Database / Bahareh Rasouli, PhD
- (B-394) Finding Needles in the Same Haystack: Comparing Designated Medical Event vs. Untargeted Approach in Signal Identification / Bahareh Rasouli, PhD
- (B-388) A Descriptive Analysis of Weight Loss Medication Use, Including GLP-1 RA Products, and Intentional Self-Harm among Patients with Obesity in FDA’s Sentinel Distributed Database / Jennifer Lyons, PhD
- (B-389) Risk of Intentional Self-Harm After GLP1-RA Use Among Patients with Type 2 Diabetes in FDA’s Sentinel Distributed Database / Jennifer Lyons, PhD
Wednesday, September 2, 2026
- Oral Presentation: Assessing the Performance of Major Congenital Malformations as a Composite Outcome in Signal Detection and Evaluation / Judy Maro, PhD / 9:30 AM - 9:45 AM / Gold Room
- Poster Session C: 12:00 PM - 1:30 PM in the Exhibit Hall
- (C-151) Uptake of Novel Anti-amyloid Therapies for Alzheimer’s Disease in the United States / Xiaojuan Li, PhD
- (C-403) Burden of Cutaneous Lupus Erythematosus in Commercially vs. Publicly Insured Patients in the FDA’s Sentinel Distributed Database / Bahareh Rasouli, PhD
- (SLC-050) Incidence Rates of Guillain-Barré Syndrome in Adult Populations in the United States: A Healthcare Database Study to Inform Vaccine Safety Studies (Spotlight Poster) / Elizabeth J. Bell, PhD
- (C-314) Development and Evaluation of Targeted Outcome Trees for Safety Surveillance using Tree-Based Scan Statistics in the Sentinel System / Yinchu Cheng, PhD
- (C-408) Risk of Renal Cell Carcinoma Following at Least 180 Days of Exposure to Canagliflozin in U.S. Patients with Type 2 Diabetes Mellitus / Po-Yin Chang, PhD
- (C-242) Dihydropyrimidine Dehydrogenase Gene Testing and Fluoropyrimidine Treatment in the United States – a Sentinel Distributed Database Study / Jamal T. Jones, PhD
